SeaStar Medical Q2 2026 revenue up 82% to $0.6M; net loss $3.7M; AKI trial 223/339

SeaStar Medical Holding Corp

Q2 net revenue $0.6M, up 82% vs $0.3M; gross margin 91% (vs 92%).
Net loss $3.7M ($0.91/share) vs $2.0M ($1.77/share) on higher R&D ($2.5M) and G&A ($1.8M).
Cash $7.0M at June 30, 2026, down from $12.0M at Dec 31, 2025.
NEUTRALIZE-AKI trial enrolled 223 of 339 adult AKI patients; completion expected year-end/Q1 2027.
CMS granted ICD-10-PCS codes for SCD therapy, effective Oct 1, 2026; added 3 children's hospitals (20 total).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.